Trending News

Blog Post


Regneron Inventory: Regeneron Earnings High, Gross sales In Line 

Regeneron Prescribed drugs (REGN) on on Thursday reported adjusted earnings of $9.89 per share on $2.53 billion in gross sales for its first quarter. In response, Regeneron inventory edged increased.


On common, analysts polled by FactSet anticipated Regeneron to earn $8.74 per share on $2.53 billion in gross sales.

Within the year-earlier interval, Regeneron earnings have been $6.60 per share and the corporate reported $1.83 billion in gross sales.

The biotech firm didn’t present full-year EPS or gross sales steerage. Analysts referred to as for adjusted earnings of $46.62 per share and $12 billion in gross sales.

In premarket buying and selling on the inventory market at this time, Regeneron inventory rose 0.7%.

Extra to comply with.

Comply with Allison Gatlin on Twitter at @IBD_AGatlin.


InMode Inventory Rises After IBD 50 Stalwart Posts Triple-Digit Revenue Development

Jazz Expects To Purchase GW Pharma — This Month — And Eyes Breakout

Choices Buying and selling: How To Begin Utilizing Choices, How To Handle Threat

Shares To Purchase And Watch: High IPOs, Massive And Small Caps, Development Shares

Get Full Entry To IBD Inventory Lists And Rankings

Supply hyperlink

Related posts

Leave a Reply

Required fields are marked *